Axsome clears Phase 3 in narcolepsy; Nkarta eyes $240M raise

Plus, news about AriBio, Fer­rer, Verge Ge­nomics, Ther­at­e­ch­nolo­gies and BioX­cel Ther­a­peu­tics:

Ax­some re­ports late-phase da­ta in nar­colep­sy: The biotech’s AXS-12 (re­box­e­tine) suc­ceed­ed in re­duc­ing cat­a­plexy at­tacks and ex­ces­sive day­time sleepi­ness, among oth­er end­points, com­pared to place­bo in the SYM­PHO­NY tri­al. This “re­sult comes very much in line with our pri­or ex­pec­ta­tions,” Mizuho Se­cu­ri­ties an­a­lysts told in­vestors. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.